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Metronidazole, a 5-nitroimidazole drug, has been the gold standard for several decades in the treatment of infections
with microaerophilic protist parasites, including Entamoeba histolytica. For activation, the drug must be chemically
reduced, but little is known about the targets of the active metabolites. Applying two-dimensional gel electrophoresis
and mass spectrometry, we searched for protein targets in E. histolytica. Of all proteins visualized, only five were found
to form adducts with metronidazole metabolites: thioredoxin, thioredoxin reductase, superoxide dismutase, purine
nucleoside phosphorylase, and a previously unknown protein. Recombinant thioredoxin reductase carrying the
modification displayed reduced enzymatic activity. In treated cells, essential non-protein thiols such as free cysteine
were also affected by covalent adduct formation, their levels being drastically reduced. Accordingly, addition of
cysteine allowed E. histolytica to survive in the presence of otherwise lethal metronidazole concentrations and reduced
protein adduct formation. Finally, we discovered that thioredoxin reductase reduces metronidazole and other nitro
compounds, suggesting a new model of metronidazole activation in E. histolytica with a central role for thioredoxin
reductase. By reducing metronidazole, the enzyme renders itself and associated thiol-containing proteins vulnerable to
adduct formation. Because thioredoxin reductase is a ubiquitous enzyme, similar processes could occur in other
eukaryotic or prokaryotic organisms.
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Introduction
Entamoeba histolytica is a microaerophilic protozoan parasite
and the causative agent of amoebiasis, a disease that affects
millions of people worldwide and claims up to 100,000
casualties per annum [1]. As is the case with other micro-
aerophilic parasitic infections, such as giardiasis (caused by
Giardia intestinalis) and trichomoniasis (caused by Trichomonas
vaginalis), the 5-nitroimidazole drug metronidazole has
established itself as the most effective treatment of amoe-
biasis. Due to the high prevalence of these infections [2] and
due to its role as a second-line defense against Helicobacter
pylori infections [3], metronidazole has been included in the
‘‘essential medicines’’ list by the World Health Organization
[4]. Metronidazole, like other nitroimidazoles, requires
reduction at the nitro group in order to be transformed into
its cytotoxic form, the nitroradical anion [5]. The activated
nitro group undergoes further reduction so that a nitro-
soimidazole is generated [6] which can react with sulfhydryl
groups [7] and with DNA [8] while being further reduced to
an amine via a hydroxylamine intermediate. In the presence
of oxygen, however, the nitroradical anion is suggested to be
rapidly reoxidized to its respective parent drug before
nitroso intermediates can be formed, i.e., a redox cycling
effect also termed ‘‘futile cycle’’ [9]. Despite the resulting
oxidative stress, this futile cycle is believed to render
metronidazole treatment safe in man. However, there are
still concerns regarding its potential carcinogenicity [10].
Since reduction of the nitro group is essential for nitro-
imidazole toxicity, extensive research has been dedicated to
enzymes that can act as metronidazole-activating nitro-
reductases. In rat liver extracts, the microsomal enzyme
NADPH-cytochrome P450 reductase was found to be respon-
sible for nitroimidazole activation [11]. The microaerophilic
parasites G. intestinalis, T. vaginalis, and E. histolytica, however,
lack mitochondria [12] but depend on substrate-level
phosphorylation [13]. In these organisms, ferredoxin, which
is being reduced by pyruvate:ferredoxin oxidoreductase
(PFOR), has been suggested to activate metronidazole [14].
Indeed, in T. vaginalis, metronidazole activation was found to
take place in the hydrogenosome [15], a hydrogen-producing
organelle in which PFOR and ferredoxin are localized [16].
Moreover, puriﬁed ferredoxin was shown to be able to reduce
various nitroimidazoles in vitro [17]; and in some highly
metronidazole-resistant laboratory T. vaginalis strains, PFOR
and ferredoxin were absent, stressing a direct relationship
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Likewise, PFOR activity [19,20] and ferredoxin levels were
reduced in metronidazole-resistant G. intestinalis strains [21].
In partially metronidazole-resistant E. histolytica, expression of
ferredoxin 1 was sharply decreased [22] although PFOR levels
remained unaltered [23]. In contrast to T. vaginalis [24],
metronidazole resistance in E. histolytica could be mainly
attributed to the increased expression of the antioxidant
enzymes peroxiredoxin [22] and superoxide dismutase [23],
rather than to loss of PFOR activity, as observed in the other
two parasites.
For several decades, great efforts have been undertaken to
deepen the understanding of metronidazole activation in the
parasitic cell, but the exact mode of action in vivo of this
pivotal drug has remained rather understudied. DNA is
suggested to be the major target of metronidazole [14,25], as
implied by several in vitro studies addressing metronidazole’s
mutagenicity and DNA-binding capability [8]. In addition, in
vitro adduct formation of nitroimidazoles with proteins and
thiols, e.g., cysteine, was also demonstrated [11], but speciﬁc
targets in the treated parasites were never deﬁned because
nitroimidazole action was assumed to be indiscriminate. As a
contribution to ﬁll this gap, it was our goal to elucidate the
processes that occur in the E. histolytica cell during metroni-
dazole treatment at concentrations that are applied during
the treatment of amoebiasis, and, if existent, identify speciﬁc
targets of metronidazole. After completion of the E. histolytica
genome project [26], application of proteomic methods such
as two-dimensional gel electrophoresis (2DE) was greatly
facilitated, permitting a comprehensive and rapid identiﬁca-
tion of proteins affected by metronidazole in treated E.
histolytica cells.
In this study, we show that, in E. histolytica, activated
metronidazole does not bind to protein indiscriminately, but
reproducibly forms covalent adducts with a small and deﬁned
number of proteins, including enzymes such as thioredoxin
reductase, superoxide dismutase, and purine nucleoside
phosphorylase, as well as the multiple-role reductant protein
thioredoxin. When recombinantly expressed in Escherichia coli
BL21 (DE3) in the presence of metronidazole, the capability
of thioredoxin reductase to reduce thioredoxin was signiﬁ-
cantly diminished. Moreover, levels of non-protein thiols, e.g.,
cysteine, were found to be drastically lowered in metronida-
zole-treated E. histolytica cells due to adduct formation
between activated metronidazole and accessible sulfhydryl
groups. In accordance with this ﬁnding, addition of cysteine
to the growth medium allowed the cells to survive otherwise
lethal metronidazole concentrations and signiﬁcantly re-
duced protein adduct formation. Finally, we propose an
alternative mode of metronidazole activation by thioredoxin
reductase, because it showed nitroreductase activity in
enzymatic assays.
Results
Metronidazole Modifies a Small Number of Proteins in E.
histolytica
After having treated E. histolytica trophozoites for different
time periods (1 h, 2 h, 3 h, and 6 h) and with varying
metronidazole concentrations (10 lM–1 mM), cell lysates
were prepared for 2DE experiments. Metronidazole concen-
trations between 50 lM and 100 lM proved to be the most
suitable because cells were viable for more than 5 h, a time
span which is sufﬁcient for the cell to react to stress by
expression of mRNA and proteins. In addition, therapeutic
levels lie within this range. Because higher metronidazole
concentrations led to rapid disintegration of the cells, and
incubation periods for more than 2 h with 50 lM metroni-
dazole did not reveal any additional changes in the protein
proﬁle, we chose exposure to 50 lM metronidazole for 2 h as
our standard condition when challenging cells with metroni-
dazole. We reproducibly found seven new protein spots on
the gels that were isolated and analyzed by mass spectro-
metric tryptic peptide ﬁngerprinting in combination with
additional veriﬁcation of selected peptide sequences by
tandem mass spectrometry (MS/MS) (identiﬁed peptides and
tandem mass spectra are listed in Figures S1–S5). These seven
spots corresponded to ﬁve proteins (Figure 1A and 1B),
identiﬁed as superoxide dismutase, purine nucleoside phos-
phorylase, thioredoxin, thioredoxin reductase, and a protein
designated as ‘‘hypothetical protein XP_650662’’ in the E.
histolytica protein database (Table 1). The last will further be
referred to as ‘‘metronidazole target protein 1’’ (Mtp1), since
its presence on 2D gels abolishes its hypothetical status.
Surprisingly, the new spots did not correspond to newly
synthesized protein, but appeared at the expense of other
neighboring spots as shifted isoforms at a more basic
isoelectric point (pI) (Figure 1A and 1B). The widths of the
shifts in pI differed with each of the proteins. Thus, it was
hypothesized that metronidazole exposure leads to modiﬁca-
tion of these ﬁve proteins, and that the newly appearing spots
correspond to isoforms of pre-existing protein in the cell.
Concomitant treatment of the cells with 100 lM cyclo-
heximide to block protein synthesis did not prevent the
appearance of the shifts on the gel when cells were exposed to
metronidazole (unpublished data). This supported our notion
that the observed spots do not correspond to newly
synthesized protein. Moreover, we did not ﬁnd any proteins
signiﬁcantly up-regulated or down-regulated in expression
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Author Summary
The protist parasites Entamoeba histolytica, Trichomonas vaginalis,
and Giardia intestinalis grow in environments with low oxygen
concentration. Infections with these parasites are commonly treated
with metronidazole, a nitroimidazole drug that must be reduced for
activation, resulting in several toxic metabolites. We examined the
soluble proteome of metronidazole-treated E. histolytica cells for
target proteins of these metabolites, applying two-dimensional gel
electrophoresis and mass spectrometry. Of about 1,500 proteins
visualized, only five formed covalent adducts with metronidazole
metabolites, including thioredoxin, thioredoxin reductase, and
superoxide dismutase. Metronidazole-bound thioredoxin reductase
displayed diminished activity. In addition to these proteins, small
thiol molecules, including cysteine, formed adducts with metroni-
dazole. Supplementation with cysteine allowed the cells to survive
otherwise lethal metronidazole concentrations. Finally, we discov-
ered that one of the modified proteins, thioredoxin reductase,
reduces metronidazole, suggesting a central role for this enzyme
with regard to metronidazole toxicity. Taken together, our work
reveals a new area of molecular interactions of activated metroni-
dazole with cellular components. Because thioredoxin reductase is a
ubiquitous enzyme, similar processes could also occur in other
eukaryotic or prokaryotic organisms.during metronidazole exposure; mRNA expression was also
not found to be altered (M. Tazreiter, unpublished data).
Thus, presumably, E. histolytica does not react to short-term
metronidazole treatment by mRNA synthesis or by synthesis
of proteins that are involved in stress response or antioxidant
defense. This indicated that the protein shifts might be due to
metronidazole adduct formation with the ﬁve proteins rather
than to a general stress response of the cell.
Unfortunately, mass spectrometric analysis of tryptic frag-
ments did not reveal any metronidazole-bound peptides.
Thus, in order to conﬁrm metronidazole binding to the
proteins, we treated the cells with other nitroimidazoles,
including the 2-nitroimidazole azomycin, and the two 5-
nitroimidazoles tinidazole and ornidazole (Figure 2A). Since
cross-resistances were reported for most of the nitroimida-
zoles [2], we expected all nitroimidazoles to give similar
results as compared to metronidazole. Again, treatment
regimens with 50 lM of the respective nitroimidazole for 2
h were chosen as the experimental conditions. Indeed, two-
dimensional (2D) gels revealed that the same proteins were
affected, but the width of the pI shifts to the basic differed
according to the varying pKa’s of the nitroimidazoles, which
can be attributed to the different side chains at the N1
position. Protein shifts upon ornidazole treatment were
slightly narrower, whereas protein shifts with tinidazole were
considerably narrower than those observed with metronida-
zole (Figure 2B). Interestingly, the 2-nitroimidazole azomycin
also shifted the same proteins. With regard to pI interval, the
shifts by azomycin were wider than shifts by the other
nitroimidazoles tested, but the amount of the respective
proteins shifted was smaller. The modiﬁcation of proteins
seemed to be independent of the position of the nitro group
in the ring, indicating a generalized pattern of nitroimidazole
action in E. histolytica.
Quantitative analysis with Melanie 2DE imaging software
indicated that, even after prolonged incubation, only a
deﬁned fraction of each protein was shifted until a certain
maximum was reached (Table 1). Thus, higher nitroimidazole
concentrations only allowed this maximum to be more
rapidly attained (unpublished data). The proteins were also
Figure 1. 2DE of E. histolytica Cell Extracts Reveals Adduct Formation upon Metronidazole Treatment
(A) The adducts formed can be identified as shifts to more basic pI values on 2D gels. Cells were treated with 50 lM metronidazole for 2 h or left
untreated. Isoelectric focusing was performed between pH 5 and pH 8; SDS PAGE was run on 12.5% polyacrylamide gels. The proteins are marked on a
section of the 2D gel of the untreated sample (upper gel image) and of the treated sample (lower gel image).
Protein 1: metronidazole target protein 1 (two shifts); protein 2: superoxide dismutase (one shift); protein 3: purine nucleoside phosphorylase (one
shift); protein 4: thioredoxin reductase (two shifts); and protein 5: thioredoxin (one shift). Unmodified proteins are marked by blue dotted circles, and
shifted proteins are indicated by red circles.
(B) The same proteins in a close-up: unmodified proteins are encircled, and the respective modified isoforms are indicated by arrows.
doi:10.1371/journal.pbio.0050211.g001
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resistant E. histolytica cells that had been continuously cultured
in the presence of 10 lM metronidazole (unpublished data).
Like others before [22,23], we were not able to obtain highly
metronidazole-resistant E. histolytica strains. Such would have
been very helpful for an assessment of the impact of the
modiﬁcations on metronidazole-mediated toxicity.
Metronidazole Reduces the Levels of Non-Protein Thiols in
the Cell
Because nitroimidazoles have been found to form adducts
with sulfhydryl group containing compounds [7], we tested
whether metronidazole treatment could reduce the levels of
non-protein thiols in the cell, e.g., cysteine, which constitutes
the major reductant in E. histolytica [27,28]. Treatment with 50
lM metronidazole for 2 h decreased non-protein thiol levels
to 49% (Figure 3A) of those in untreated cells (11 fmol/cell),
whereas additional 50 mM cysteine (17 mM cysteine
constitutes the standard concentration in TYI-S-33 medium),
led to accumulation of cysteine in the cell and raised non-
protein thiol levels by about 180%, to approximately 31 fmol/
cell. When metronidazole and cysteine were used in combi-
nation, thiol levels were also sharply decreased (54% of the
untreated state). Since cysteine could not accumulate intra-
cellularly in the presence of metronidazole (the observed 5%
difference between total free-thiol levels of cells treated with
metronidazole alone and those treated with metronidazole in
combination with cysteine, is statistically not signiﬁcant),
these results indicate that cysteine levels in the cell are
diminished by metronidazole.
As the observed decrease in non-protein thiol levels could
also be the consequence of oxidative stress, e.g., oxidation of
sulfhydryl groups by hydrogen peroxide, we attempted to
verify covalent adduct formation of metronidazole with
sulfhydryl groups by exposing the cells to 50 lM metronida-
zole under anaerobic (Merck Anaerocult A, 0% O2 and 18%
CO2), microaerophilic (Merck Anaerocult C, 5% O2 and 8%
CO2), and aerobic conditions (aerated vials), respectively. We
reasoned that, if the decrease in thiol levels were to be
attributed to oxidative stress, exposure of the cells to
metronidazole under aerobic conditions would result in even
more strongly reduced thiol levels, whereas, under anaerobic
conditions, the observed effect should be signiﬁcantly miti-
gated or even absent. However, our experiment showed that
the reduction of thiol levels, to 36% of the level of untreated
cells, was the most strongly pronounced after metronidazole
exposure under anaerobic conditions (Figure 3B), followed by
exposure to metronidazole under microaerophilic conditions,
with 51%, and then under aerobic conditions, with 54%. Thus,
oxygen did not promote, but conversely, counteracted the
reduction of thiol levels upon metronidazole exposure, which
strongly suggests that covalent adduct formation of activated
metronidazole with thiol groups is the reason for the decrease
in non-protein thiol levels. Moreover, these results are in line
with the ﬁnding that oxygen can detoxify nitroradical anions
and regenerate the parent drug by snatching the electron
from the nitro group [9]. However, this effect was not as
pronounced as anticipated, because reoxidation of the
metronidazole radical anion by oxygen was incomplete,
leading to almost halved non-protein thiol levels, even under
aerobic conditions. Interestingly, adduct formation with the
ﬁve proteins found was not affected in the presence of higher
oxygen concentrations when cells were treated with 50 lM
metronidazole for 2 h (unpublished data).
Azomycin Also Diminishes Non-Protein Thiols but to a
Lesser Extent
In order to evaluate the extent to which the observed
decrease in non-protein thiol levels contributes to metroni-
dazole toxicity, we treated cells with azomycin, which had
been found to be by far less toxic to E. histolytica than
metronidazole (D. Leitsch, unpublished data). Indeed, non-
protein thiol levels were found to be affected by azomycin,
even if considerably less than by metronidazole, paralleling
the observation that azomycin shifts the same proteins as
metronidazole, albeit to a smaller extent. Under anaerobic
conditions, a drop to 65% of the original level when treating
cells with 50 lM azomycin for 2 h, as compared to a drop to
36% when treating the cells with metronidazole, was observed
(Figure 3B). In the presence of oxygen, non-protein thiol
levels after exposure to azomycin were only slightly reduced:
84% (microaerophilic) and 82% (aerobic), respectively, of the
non-protein thiol levels were retained as compared to
untreated cells. Interestingly, higher oxygen levels counter-
acted adduct formation of azomycin with non-protein thiol
groups more strongly than was the case with metronidazole.
As compared to anaerobic conditions, 49% less adduct
formation with azomycin (a drop of non-protein thiols of
only 18%—to 82% of the untreated sample—instead of a
drop of 35%—to 65%) and 28% less adduct formation with















1 Metronidazole target protein 1 60% XP_650662 14359 6.28 2 2 3 0.3 100%
2 Superoxide dismutase 67% XP_648827 22030 6.30 1 0.05 50%
3 Purine nucleoside phosphorylase 59% XP_655398 34754 5.63 1 0.2 ,25%
4 Thioredoxin reductase 62% XP_655748 33742 5.93 2 0.015 and 0.010 25%
5 Thioredoxin 66% XP_656726 11632 5.30 1 0.5 50%
The proteins were identified by mass spectrometric tryptic peptide fingerprinting in combination with additional verification of selected peptide sequences by MS/MS. The proportion of
identified peptides in the respective protein is given as sequence coverage (for identified peptides and tandem mass spectra, see Figures S1–S5). The numbering corresponds to that in
Figure 1A and 1B.
MW, molecular weight.
doi:10.1371/journal.pbio.0050211.t001
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sample—instead of a drop of 64%—to 36%) were observed
when treating cells under aerophilic conditions. Differences
between microaerophilic and anaerobic conditions with
regard to their impact on the decrease of non-protein thiol
levels in the presence of metronidazole or azomycin were
hardly signiﬁcant, if existent.
Cysteine Confers Protection against Metronidazole and
Reduces Adduct Formation of Metronidazole with Proteins
Although non-protein thiol levels were only insigniﬁcantly
higher in cells that were treated with metronidazole and
cysteine in combination, as compared to non-protein thiol
levels in cells treated with metronidazole alone, we observed
that the cells were not rounding off and disintegrating in the
presence of higher cysteine levels. Therefore, we tested
whether raised cysteine levels in the medium could protect
E. histolytica during metronidazole treatment. Cells were
treated with 30 lMo r5 0lM metronidazole either in the
presence or absence of additional 50 mM cysteine (67 mM in
total) (Figure 3C). Addition of 50 mM cysteine slightly
impaired viability; only 83% of the cells were still viable
after 20 h of incubation. In the cultures treated with 30 lM
metronidazole alone, only 23% of the cells were still viable
after the same time span, whereas 50 lM of metronidazole
was sufﬁcient to kill almost all cells in the culture (2% viable
cells). However, 86% of the cells in the culture treated with 30
lM metronidazole and 71% of the cells treated with 50 lM
metronidazole were still viable after 20 h when 67 mM
cysteine was present in the growth medium. These results
clearly indicate that cysteine strongly counteracts metroni-
dazole toxicity in E. histolytica.
We speculated that the protective effect of cysteine might
be due to less metronidazole adduct formation with proteins,
because we expected free cysteine to compete with proteins
for activated metronidazole. Thus, we assessed the inﬂuence
of raised cysteine levels on adduct formation of metronida-
zole with the ﬁve proteins identiﬁed. Additional 50 mM
cysteine markedly reduced metronidazole adduct formation
with protein when cells were treated with 50 lM metronida-
zole for 2 h (Figure 3D). The shifts in pI of superoxide
dismutase, thioredoxin, and Mtp1 were clearly diminished in
this case, whereas thioredoxin reductase was only subject to
putatively one modiﬁcation and purine nucleoside phosphor-
ylase remained unmodiﬁed. The latter two observations were
not always made when repeating the experiment, but a very
distinct decrease of adduct formation with all ﬁve proteins
was perfectly reproducible. These results suggest that non-
protein cysteine competes with proteins in the formation of
adducts with activated metronidazole, and that the observed
protective effect of cysteine during metronidazole exposure
might be due to fewer protein adducts formed.
Expression of Recombinant E. histolytica Thioredoxin
Reductase and E. histolytica Thioredoxin
As a result of our observation that metronidazole adducts
are also formed in Es. coli under microaerophilic conditions,
albeit at much higher metronidazole concentrations than is
the case in E. histolytica (unpublished data), we decided to
recombinantly express E. histolytica thioredoxin reductase and
E. histolytica thioredoxin in Es. coli either in the presence or in
the absence of metronidazole. We speculated that this
strategy would allow us to obtain a large quantity of
metronidazole-bound protein that could aid in the mass
spectrometric identiﬁcation of the observed modiﬁcations. In
addition, the inﬂuence of metronidazole adduct formation
on protein function could be assayed in vitro with the
modiﬁed and unmodiﬁed recombinant proteins at hand. As
thioredoxin and thioredoxin reductase are of central
importance for the cell’s physiology [29], these two proteins
were of particular interest to us. Moreover, human [30] and
Arabidopsis thaliana [31] thioredoxin reductases were shown, in
addition to their intrinsic disulﬁde reductase activity, to
reduce nitro compounds such as tetryl or 1-chloro-2,4-
Figure 2. Different Nitroimidazoles Shift the Same Target Proteins to a
Different Extent
(A) The nitroimidazoles used in this study are shown: the 5-nitro-
imidazoles metronidazole (1), tinidazole (2), and ornidazole (3), and the
2-nitroimidazole azomycin (4). Different side chains result in different
contributions of the compounds to the pI shifts on 2D gels.
(B) Adduct formation of the same proteins with different nitroimidazoles.
The same proteins were shifted with the 5-nitroimidazoles metronida-
zole, ornidazole, and tinidiazole, and with the 2-nitroimidazole azomycin.
The width of the shifts in pI depended on the total charge of the
nitroimidazole used, which is determined by its side chains. Shifts are
exemplified by two of the proteins found: superoxide dismutase and
metronidazole target protein 1. The unmodified proteins are encircled,
and shifted proteins are indicated by arrows.
doi:10.1371/journal.pbio.0050211.g002
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determine in vitro whether E. histolytica thioredoxin reductase
can, in addition to its role as a disulﬁde reductase, reduce
nitroimidazoles.
Recombinant E. histolytica thioredoxin reductase (recEh
TrxR) and recombinant E. histolytica thioredoxin (recEh Trx)
were produced in Es. coli BL21 (DE3) cells and puriﬁed on Ni-
NTA columns via their carboxy-terminal hexahistidine tags.
Figure 3. Interdependence of Non-Protein Thiols and Metronidazole Toxicity
(A) Metronidazole diminishes non-protein thiol levels in the cell. Determination of total non-protein sulfhydryl groups (fmol/cell), i.e., free thiols, in the
cell after treatment of E. histolytica cells for 2 h with either additional 50 mM cysteine (67 mM in total) or 50 lM metronidazole alone, or both in
combination. The experiment was independently performed three times. Vertical bars indicate standard deviations.
(B) The decrease of non-protein thiols is most pronounced under anaerobic conditions when treating cells with metronidazole and azomycin. Cells were
either treated with 50 lM of metronidazole (left) or azomycin (right) for 2 h under anaerobic (0% O2 and 18% CO2), microaerophilic (5% O2 and 8% CO2),
and aerobic (21% O2 and 0.4% CO2) conditions. Values are given as percentages of non-protein thiol concentrations of the respective untreated samples.
(C) Cysteine counteracts metronidazole toxicity. E. histolytica cells were treated with either 30 lMo r5 0lM of metronidazole in the presence or absence
of additional 50 mM cysteine for 20 h. Viability of cells was determined by trypan blue exclusion. The experiment was independently repeated three
times. Numbers of viable cells are given as percentages of total cell counts. Vertical bars indicate standard deviations.
(D) Cysteine reduces adduct formation of proteins with metronidazole. Cells were treated with 50 lM of metronidazole either in the presence or
absence of additional 50 mM cysteine for 2 h. Afterwards, cell lysates were prepared, and the extent of adduct formation of superoxide dismutase (1),
thioredoxin reductase (2), thioredoxin (3), metronidazole target protein 1 (4), and purine nucleoside phosphorylase (5) with metronidazole was
visualized by 2DE. Unmodified proteins are encircled, and shifted proteins are indicated by arrows.
doi:10.1371/journal.pbio.0050211.g003
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Thioredoxin Reductase and Nitroimidazole ActionRecEh TrxR had a deep yellowish color that can be attributed
to its FAD or FMN cofactor [32].
Detection of Metronidazole Adducts on recEh TrxR and
recEh Trx after Expression in the Presence of
Metronidazole
When Es. coli BL21 (DE3) cells were treated with 1 mM
metronidazole during recEh TrxR and recEh Trx expression,
the recombinant proteins were efﬁciently modiﬁed by
metronidazole as veriﬁed by 2DE (unpublished data). In
contrast to our failed attempts to identify metronidazole on
peptides that were directly isolated from 2D gels, we
observed, by liquid chromatography electrospray ionization
quadrupole time-of-ﬂight tandem mass spectrometry (LC-
ESI-QTOF-MS) of intact proteins, that a high proportion of
recEh TrxR and recEh Trx displayed a shift in molecular mass
(Figure 4A). The shift in the deconvoluted spectra of both
recEh Trx and recEh TrxR (but here only illustrated with
recEh Trx), corresponded to a mass gain of 141 Da. This is in
good agreement with the in vitro reaction scheme for 5-
nitroimidazoles as proposed by Wislocki and colleagues [33]
(Figure 4B). In this scheme, the activated 5-nitroimidazole is
ﬁrst reduced to an electrophilic nitrosoimidazole, which is
subsequently attacked at its C4 atom by a sulfhydryl group.
This is accompanied by further reduction to a hydroxylamine
group, which is ﬁnally reduced to an amino group. Thus, the
nitroimidazole loses two oxygen atoms from the nitro group
and one proton from C4, and gains two hydrogens, resulting
in a decrease in mass of 31 Da. At physiological pH and under
the conditions applied during LC-ESI-QTOF-MS, however,
the amino group is protonated, leading to a total mass
decrease of only 30 Da. Since metronidazole has a mass of
171.16 Da, a protein that binds metronidazole can be
expected to increase in mass by about 140 Da because it
gains 141 Da from the bound 5-aminoimidazole derivate of
metronidazole but loses the proton of a sulfhydryl group.
When allowing for the methodological restraints of the LC-
ESI-QTOF-MS instrument, which has a mass deviation of 64
Da when analyzing a protein of the size of recEH Trx, the
calculated theoretical mass gain of 140 Da after modiﬁcation
by activated metronidazole corresponds well with the
observed shift of 141 Da. In order to check whether the
proposed model also applies for other 5-nitroimidazoles than
metronidazole, we expressed recEh TrxR and recEh Trx in
presence of tinidazole, which has a molecular mass of 247.3
Da. The result obtained with metronidazole was paralleled by
that with tinidazole (Figure 4A); the shifts in the deconvo-
luted spectra amounted to 217 Da (molecular weight of the
nitroimidazole less 30 Da). Moreover, it is important to add
that the proposed model for nitroimidazole binding is also
supported by the fact that, on 2D gels, the pI values of all ﬁve
proteins identiﬁed were shifted to the basic, probably due to
the reduction of the nitro group of the nitroimidazoles to a
basic amino group.
Additional peaks that can be observed on the mass spectra
of metronidazole- and tinidazole-bound recEh Trx corre-
spond to mass increments of approximately 16 Da or 32 Da,
and very likely can be attributed to oxidation (one or two
oxygen atoms, respectively). Not unexpectedly, reactive oxy-
gen species that are generated during nitroimidazole treat-
ment led to oxidation of proteins (e.g., recEh Trx) and,
probably, other cell constituents.
Unfortunately, our attempts so far to pinpoint the
modiﬁcations to speciﬁc tryptic peptide fragments from
recEh Trx and recEh TrxR have been as unsuccessful as had
been our attempts to identify the modiﬁcations on E.
histolytica proteins directly isolated from 2D gels. Obviously,
the nitroimidazole adducts were not stable under the
experimental conditions applied, possibly because incubation
periods with trypsin (overnight at 37 8C) were too long or the
conditions during LC-ESI-QTOF-MS were too harsh. We will,
therefore, intensify our efforts in the future and modify the
standard protocols accordingly.
Metronidazole-Modified recEh TrxR Displays Considerably
Reduced Thioredoxin Reductase Activity
Thioredoxin reductase activity of recEh TrxR (applied at a
concentration of 148 nM) was veriﬁed (Figure 5) by reduction
of the disulﬁde 5,59-dithiobis-(2-nitrobenzoic acid) (DTNB) to
2-nitro-5-thiobenzoic acid (TNB) via recEh Trx (applied at a
concentration of 174 nM). Speciﬁc reduction of recEh Trx
was determined by subtracting the ground-level reduction of
DTNB (206 nmol min
 1 mg
 1) by recEh TrxR and was found
to amount to 559 nmol min
 1 mg
 1 (which equals a turnover
of approximately 23.5 min
 1). RecEh TrxR and its substrate,
recEh Trx, were used in roughly equimolar amounts because
our 2D gels suggested that both proteins are about equally
abundant in the cell. Because we wanted to stay as close to
physiological conditions as possible, we did not apply such a
high excess of the substrate to the enzyme as would be
necessary for the exact determination of the kinetic constants
of recEh TrxR. Nevertheless, the activity of recEh TrxR,
determined by us, is in good accordance with the thioredoxin
reducing activity of E. histolytica thioredoxin reductase as
determined just recently by Arias and colleagues [34].
We used metronidazole-modiﬁed recEh TrxR and recEh
Trx for an estimation of the inﬂuence of metronidazole on
protein function. Thioredoxin reducing activity of metroni-
dazole-modiﬁed recEh TrxR dropped by more than 50% to
265 nmol min
 1 mg
 1 (Figure 5), and when used in
combination with metronidazole-modiﬁed recEh Trx, the
efﬁciency of recEh Trx reduction by recEh TrxR was even
further diminished (220 nmol min
 1 mg
 1). When assaying
metronidazole-modiﬁed recEh Trx alone, disulﬁde reduction
lay also clearly below (427 nmol min
 1 mg
 1) the reduction
rate as compared to using unmodiﬁed forms of both recEh
TrxR and recEh Trx (559 nmol min
 1 mg
 1).
RecEh TrxR Displays Nitroreductase Activity In Vitro
Using a recEH TrxR concentration of 118 nM (equal to 4
lg/ml), CDNB reduction was determined by measuring
NADPH consumption at 340 nm (Table 2). Nitroreductase
activity amounted to 233 nmol min
 1 mg
 1 (7.8 reduction
events per minute per molecule of recEh TrxR) when using
CDNB as the substrate at a concentration of 100 lM.
Unfortunately, the assay was heavily disturbed by the
absorbances of the nitroimidazoles. As an alternative method
(Table 2), nitroreductase activity of recEh TrxR was indirectly
determined by measuring reduction of cytochrome c by
reduced nitro compounds [30], or by superoxide radical
anions generated by the transfer of an electron from
nitroradical anions to oxygen, respectively. In both cases,
reduction of cytochrome c could be attributed to the
previous reduction of the assayed nitro compounds, i.e.,
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(A) Detection of mass increment by LC-ESI-QTOF-MS. Total protein mass was determined using LC-ESI-QTOF-MS after His-Tag purification of the protein.
When BL21 (DE3) cells were not exposed to metronidazole or tinidazole during expression of recEh Trx, a single peak in the deconvoluted mass
spectrum was observed. This peak was in good agreement with the expected mass of 12,322 Da when taking into account that methionine at position
1 is removed, six histidines are attached at the C-terminus, and one cysteine-disulfide bridge is formed. When BL21 (DE3) cells were exposed to
metronidazole or tinidazole during recombinant protein expression, recEh Trx modified with metronidazole or tinidazole eluted slightly earlier on the
LC than unmodified recEh Trx. The determined mass increments, i.e., 141 Da with metronidazole treatment and 217 Da with tinidazole, support the
reaction scheme for 5-nitroimidazoles as proposed by Wislocki and colleagues [33]. Additional peaks in the spectra of modified recEh Trx correspond to
mass increments of approximately 16 Da or 32 Da, and can be attributed to bound oxygen (a single oxygen or two).
(B) Model of adduct formation of 5-nitroimidazoles with sulfhydryl groups. After the uptake of 5-nitroimidazoles into the cell (1), the nitro group is
reduced to form a nitro radical anion (2). According to the model of Wislocki and colleagues [33], the nitro radical anion is further reduced ( 16 Da) to a
highly reactive 5-nitrosoimidazole (3) which forms adducts ( 2 Da) with sulfhydryl groups via the C4 of the imidazole ring (4). Adduct formation is
accompanied by reduction (2 e
 ) of the nitroso group to a hydroxylamine group (þ2 Da). Subsequently (5), the hydroxylamine group is further reduced
(2 e
 ) to an amino group ( 16 Da), resulting in the stable and non-reactive 5-aminoimidazole adduct. At physiological pH or under the conditions
applied during MS, the amino group is protonated (þ1 Da) (6). A total of six e
  is necessary at the nitrogen of the former nitro group to obtain the
aminoimidazole adduct which, compared to the corresponding nitroimidazole, decreases in mass by 30 Da. The bound protein or thiol loses one proton
during adduct formation. Thus, in total, nitroimidazole adducts gain the molecular mass of the respective nitroimidazole less 31 Da.
doi:10.1371/journal.pbio.0050211.g004
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Thioredoxin Reductase and Nitroimidazole ActionCDNB, the 2-nitroimidazole azomycin, and the 5-nitro-
imidazole metronidazole, by recEh TrxR (4 lg/ml). As
expected, CDNB was readily reduced at a rate of 171 nmol
 1
mg
 1 at concentrations as low as 10 lM (Table 2). This rate
lies in the range of the determined nitroreductase activity of
recEh TrxR when measuring NADPH consumption. The 36%
higher reduction of CDNB in the ﬁrst assay is likely due to the
10-fold higher CDNB concentration used. The 2-nitroimida-
zole azomycin was also readily reduced at a concentration of
100 lM( 6 3n m o lm i n
 1 mg
 1). The reduction rate of
metronidazole (1 mM) amounted to 31 nmol min
 1 mg
 1.
All values given above have been corrected for the ground-
level activity of recEh TrxR, i.e., the reduction of molecular
oxygen in the assay buffer, resulting in the formation of
superoxide radical anions that, in turn, can reduce cyto-
chrome c. In the absence of recEh TrxR, no reduction of
cytochrome c was observed. In contrast to thioredoxin
reductase activity, nitroreductase activity was not impaired
with metronidazole-bound recEh Trx (unpublished data).
This is possibly due to the fact that the ﬂavin cofactor rather
than the enzymatic site of recEh TrxR is responsible for
nitroreduction [31].
In order to distinguish between direct reduction of
cytochrome c by nitroradical anions and between reduction
of cytochrome c by superoxide radical anions that had
previously been formed by the transfer of the electron of the
nitroradical anion to molecular oxygen, superoxide dismu-
tase was added to the reactions in about 20-fold excess (2.5
lM) (Table 2). The addition of superoxide dismutase
completely abolished ground-level reduction of cytochrome
c by EhTrxR and decreased cytochrome c reduction in the
presence of 10 lM CDNB to 47% of the original value.
Cytochrome c reduction in the presence of 100 lM azomycin
was diminished to 53%, whereas 75% of the original value
was retained with 1 mM metronidazole. Higher concentra-
tions of superoxide dismutase did not lead to further
decreases in cytochrome c reduction. Thus, in the case of
CDNB and azomycin, roughly half of the cytochrome c
reduction is mediated by superoxide radical anions, whereas
the metronidazole nitroradical anions directly transferred
most of the electrons to cytochrome c. These results provide
direct evidence for the formation of superoxide radical
anions upon nitroimidazole treatment in general and within
limits upon metronidazole treatment, and thereby for the
generation of oxidative stress in the microaerophilic cell.
Discussion
In this study, we show for the ﬁrst time that metronidazole
forms adducts with proteins and non-protein thiols in an in
vivo model, i.e., a parasite that is commonly treated with this
drug. The shifts in masses, found on the mass spectra of
metronidazole-bound recEh Trx and recEh TrxR, conﬁrmed
the in vitro model for 5-nitroimidazole adduct formation by
Wislocki and colleagues [33] (Figure 4B). In contrast to the in
vitro data from the late 1970s and early 1980s, however, we
found discrete changes in the protein proﬁle of E. histolytica
after metronidazole treatment, i.e., modiﬁcation of ﬁve
proteins, rather than indiscriminate protein adduct forma-
tion. It is possible that there are some more proteins affected,
because 2DE does not cover the whole proteome of a given
organism. Very large proteins, low-abundance proteins such
as transcription factors, and highly hydrophobic membrane
proteins that could also potentially form adducts with
nitroimidazoles cannot be identiﬁed by our approach.
Nevertheless, even if allowing for these restraints, the number
of affected proteins can be expected to remain small.
Because we made similar observations with Entamoeba dispar
(the nonpathogenic relative of E. histolytica), G. intestinalis, T.
vaginalis, and Es. coli (unpublished data), we suggest that
adduct formation with a deﬁned subset of proteins can take
place in any organism that is treated with nitroimidazoles
(unpublished data): the presumed reduction of the nitro
group to an amino group during adduct formation with the
proteins leads to easily discernable shifts on 2D gels to more
basic pI values. It is, therefore, interesting to speculate that
nitroimidazoles could be an invaluable tool in proteomics,
because our data suggest that they allow identiﬁcation of
nitroreductases and associated proteins by shifting them to
more basic pI values that can easily be detected on 2D gels.
Apart from forming covalent adducts with proteins,
metronidazole also diminishes non-protein thiol levels in
the cell (Figure 3A), including that of cysteine. The observed
decrease in non-protein thiol levels is due to covalent adduct
formation with metronidazole and not due to oxidative stress
generated by the activated drug, because the drop in thiol
levels was most pronounced in the total absence of oxygen
and least pronounced under aerobic conditions (Figure 3B).
Since cysteine is a compound of essential importance to E.
histolytica cell physiology [35], and because it is assumed to
function as the major reductant in the cell [27], its depletion
could contribute to metronidazole toxicity in E. histolytica.O n
the other hand, cysteine could also predominantly have a
protective role because other essential thiols in the cell, such
as coenzyme A, might also form adducts with metronidazole.
Interestingly, after 2 h of incubation, non-protein thiol levels
in cells treated with 50 lM metronidazole and 50 mM cysteine
were almost diminished to the same extent as non-protein
thiol levels in cells treated with metronidazole alone (Figure
Figure 5. Metronidazole Binding Diminishes Thioredoxin Reductase
Activity of recEh TrxR
After expression of recEH TrxR and recEH Trx in the presence or absence
of metronidazole for 3 h, proteins were isolated and thioredoxin
reductase activity of recEh TrxR was determined by reduction of DTNB
via recEh Trx as measured at k¼412 nm (OD412). Diamonds (¤) indicate
the use of unmodified forms of both recEh TrxR and recEh Trx, crosses (x)
the use of unmodified recEH TrxR and metronidazole-modified recEh Trx.
Squares (&) indicate the use of metronidazole-modified recEh TrxR and
unmodified recEh Trx, and triangles (m) the use of modified forms of
both recEh TrxR and recEh Trx.
doi:10.1371/journal.pbio.0050211.g005
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cysteine in the growth medium, however, might lead to
consumption and, consequently, detoxiﬁcation of metroni-
dazole. This is indicated by the observation that the toxic
effect of metronidazole was drastically reduced after addition
of 50 mM cysteine, because more than 70% of the cells in a
culture survived 20-h exposure to (otherwise lethal) 50 lM
metronidazole (Figure 3C). In addition, raised cysteine levels
also led to less protein adduct formation after metronidazole
treatment (Figure 3D), which indicates the interdependence
of non-protein and protein sulfhydryl groups with regard to
metronidazole toxicity and which could be an explanation for
the protective effect of cysteine during metronidazole
exposure.
Treatment of E. histolytica cells with the clearly less toxic 2-
nitroimidazole azomycin also led to the modiﬁcation of the
ﬁve proteins found (Figure 2B) and a decrease in non-protein
thiol levels (Figure 3B), albeit to a far smaller extent.
Interestingly, the capability of azomycin to diminish non-
protein thiol levels in the cell was also much more decreased
by oxygen than was the case with metronidazole. Thus, the
lower toxicity of azomycin could be based on its reduced
tendency to form adducts with sulfhydryl groups and on its
higher reactivity with oxygen (Table 2).
A potentially detrimental effect of metronidazole binding
to protein function is indicated by the signiﬁcant decrease of
the thioredoxin reductase activity of recEh TrxR after
metronidazole treatment (Figure 5). However, it is also
conceivable that the observed oxidation of several amino
acids concomitant with nitroimidazole binding, as observed
with recEh Trx (Figure 4A), contributes to a diminished
enzymatic function.
E. histolytica thioredoxin reductase was found to be a
nitroreductase that is able in vitro to reduce CDNB, as well as
the nitroimidazoles azomycin and metronidazole (Table 2). In
contrast to thioredoxin reductase activity of recEh TrxR,
nitroreductase activity of metronidazole-bound recEh TrxR
was not decreased (unpublished data), suggesting that nitro-
reduction is directly exerted by the FAD or FMN cofactor
[31,32]. Azomycin (2.4 min
 1 at a concentration of 100 lM)
was more effectively reduced in the nitroreductase assay than
metronidazole (1.2 min
 1 at a concentration of 1 mM),
possibly due to the higher redox potential of azomycin (E
1
7¼
 418 mV) as compared to metronidazole (E
1
7¼ 486 mV) [36].
Interestingly, CDNB, which was the compound tested to be
most efﬁciently reduced (6 min
 1 at a concentration of 10
lM) by recEh TrxR, exerted only a mildly toxic effect on E.
histolytica in our experimental setting—arguably because it
does not form adducts with the same proteins as observed
with nitroimidazoles and because it does not lead to a
reduction of non-protein thiol levels in the cell (D, Leitsch,
unpublished data). It is also possible, however, that CDNB
does not enter the cell as readily as metronidazole.
When superoxide dismutase was added to the reactions,
cytochrome c reduction rates in the presence of CDNB and
azomycin were approximately halved (47% and 53%,
respectively), whereas in the presence of metronidazole,
75% of the original rate was retained. These ﬁndings provide
direct evidence for the generation of oxidative stress upon
nitroimidazole treatment, because superoxide radical for-
mation is evident. However, reoxidation of metronidazole by
oxygen, with only 25% of the metronidazole nitroradical
anions reoxidized, was by no means as complete and as rapid
as anticipated [9]. Thus, it is doubtful whether the futile-cycle
effect is really as inﬂuential on metronidazole toxicity as has
been suggested.
Although the nitroreductase activity of recEH TrxR is
rather low, it is comparable to the nitroreductase activities
determined for A. thaliana and mammalian thioredoxin
reductases [30,31]. According to our quantitative evaluations
of 2D gels from E. histolytica cell extracts, thioredoxin
reductase amounts to approximately 0.2% of the total protein
in the cell, equaling 10–20 million copies per cell. Our
estimate of the concentration of non-protein sulfhydryl
groups amounts to 11 fmol/cell, i.e., only a 400-fold excess of
non-protein sulfhydryl group levels over those of thioredoxin
reductase. It is therefore conceivable that nitroimidazole
reduction by thioredoxin reductase plays an important role in
the decrease of non-protein thiol concentrations in the
treated cell. In this context, it is interesting to note that
studies in G. intestinalis have shown that the turnover of
metronidazole reduction by puriﬁed ferredoxin was also not
Table 2. Nitroreductase Activity of RecEh TrxR















Percentage of Electrons Directly Transferred
to Cytochrome c by Nitroradicals
CDNB (10 lM) ND ND 171 6 21 6 6 0.6 47 6 6
CDNB (100 lM) 233 6 38 7.8 6 1.3 ND ND ND
Azomycin (100 lM) ND ND 63 6 52 . 4 6 0.24 53 6 15
Metronidazole (1 mM) ND ND 30 6 31 . 2 6 0.12 75 6 5
Nitroreductase activity of E. histolytica thioredoxin reductase was first determined by measuring NADPH consumption at k ¼ 340 nm (De340 being 6.2 mM
 1 cm
 1), using CDNB as the
substrate (far left column). Reduction rates of nitroimidazoles were not determined for technical reasons. As a second approach, nitroreductase activity of E. histolytica thioredoxin
reductase was determined at k¼550 nm (De550 being 20 mM
 1 cm
 1) (far right column) by measuring cytochrome c reduction by nitroradical anions or by superoxide radical anions that
had previously been formed by transfer of an electron from a nitroradical anion to molecular oxygen in the assay buffer. The nitro compounds, in turn, had been reduced by E. histolytica
thioredoxin reductase. CDNB, azomycin, and metronidazole were used as substrates for E. histolytica thioredoxin reductase in the concentrations indicated. Enzyme activities and turnover
rates are listed and standard deviations are indicated. The proportions of the electrons that are directly transferred from the nitroradicals to cytochrome c, as determined by addition of a
20-fold excess of superoxide dismutase, are given as percentages of the overall reduction rates.
ND, not determined.
doi:10.1371/journal.pbio.0050211.t002
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 1), when puriﬁed PFOR instead of
cell extract was used as the electron donor for ferredoxin [20].
We suggest that, due to spatial proximity to the reactive
nitroimidazole species generated, reduction of nitroimida-
zoles by thioredoxin reductase renders this enzyme vulner-
able to nitroimidazole adduct formation. Thioredoxin,
superoxide dismutase, and Mtp1, in turn, can be expected
to be localized in proximity to thioredoxin reductase or to
interact with thioredoxin reductase. This could render these
proteins prone to nitroimidazole modiﬁcation as well.
Proteins that do not interact with thioredoxin reductase are
likely to be less affected, because activated nitroimidazoles
react with non-protein thiols or other compounds before
they can react with proteins that are more distant to the site
of nitroimidazole reduction. Thioredoxin needs to be
reduced by thioredoxin reductase in order to fulﬁll its
multiple purpose as a reductant protein [29], whereas
superoxide dismutase could be required to remove super-
oxide anion radicals that are indirectly generated by the
nitroreductase activity of thioredoxin reductase. Superoxide
dismutase might minimize the damage caused by superoxide
when being positioned near thioredoxin reductase. Metroni-
dazole target protein 1 (Mtp1) has no close homolog in any
other organism whose genome has been sequenced so far, but
it contains an O-glycosyl hydrolase domain and displays
extended homology to an a-amylase in E. histolytica. Recent
research suggests that thioredoxins are also of decisive
importance for starch degradation in plants. Very strong
evidence has been presented for thioredoxin-mediated
regulation of a-amylases in barley grain [37]. Reduction of
intramolecular disulﬁde bonds in amylases renders these
enzymes more soluble, which is a prerequisite for amylase
activity. Since Mtp1, as a protein of about 14 kDa, contains as
many as six cysteines, it is conceivable that it requires
thioredoxin in order to be functional. In the case of purine
nucleoside phosphorylase, the situation could be different
because arsenate reductase activity has been observed with
human purine nucleoside phosphorylase [38]. This gives
reason to speculate about the potential nitroreductase
activity of the corresponding enzyme in E. histolytica. Possibly,
purine nucleoside phosphorylase binds to the imidazole ring
of nitroimidazole compounds,because purines have an
imidazole moiety. However, in the same study, the authors
found arsenate reductase activity to strongly depend on
reductants, especially DTT, which suggests that purine
nucleoside phosphorylase could require reduction by thio-
redoxin as well. Very surprisingly, we did not ﬁnd PFOR or
ferredoxin among the proteins forming adducts with metro-
nidazole, although PFOR can be readily found on 2D gels
when analyzing E. histolytica cell extracts [39]. High percentage
(20%) acrylamide gels did not show any shifted proteins in
the range of ferredoxin (approximately 6 kDa). It has been
reported that, in contrast to T. vaginalis or G. intestinalis, PFOR
was not found to be down-regulated in metronidazole-
resistant E. histolytica [22,23], which supports the assumption
that PFOR might not be involved in nitroimidazole activation
in this organism. However, this is questioned by the fact that
ferredoxin 1 levels were found to be decreased in metroni-
dazole-resistant E. histolytica [22]. At the moment, we do not
have a conclusive explanation for these contradictory results,
but it is conceivable that down-regulation of ferredoxin 1 in
metronidazole-resistant E. histolytica could also be an accom-
panying effect of down-regulation of thioredoxin and
thioredoxin reductase. As a potential parallel, thioredoxin
has been shown to regulate a large number of proteins in
plants, including enzymes involved in glycolysis such as
aldolase, enolase, glyceraldehyde 3-phosphate dehydrogenase,
and triose phosphate isomerase [40]. Thus, loss of thioredoxin
activity or diminished thioredoxin levels in the cell could also
impair the cellular metabolism, consequently leading to a
down-regulation of ferredoxin.
Interestingly, a thioredoxin reductase originally with
different annotation had been sequenced before the E.
histolytica genome project had started. It was called disulphide
oxidoreductase (Eh34) [41] or later, ﬂavin reductase, [22], and
was found to have reduced expression in metronidazole-
resistant E. histolytica [22]. The very slight differences in the
sequences of thioredoxin reductase from the genome project
and Eh34 (2% on the DNA level) and the absence of an exact
copy of the Eh34 gene in the genome database have not been
resolved conclusively (I. Bruchhaus, personal communica-
tion). Eh34 was hypothesized by the authors to be involved in
metronidazole activation because recombinant overexpres-
sion of Eh34 in E. histolytica rendered cells more vulnerable to
metronidazole [22]. These unexpected ﬁndings of our
colleagues strengthen our argument that thioredoxin reduc-
tase is involved in metronidazole activation in E. histolytica
because down-regulation of thioredoxin reductase, as an
enzyme known to be involved in oxidative stress response [42],
would otherwise be highly counterproductive during metro-
nidazole exposure that leads to the formation of reactive
oxygen species, at least under microaerophilic conditions.
The data gathered prompted us to propose a model of
metronidazole action in E. histolytica that implies, apart from
generation of reactive oxygen species in the presence of
oxygen, that toxicity of metronidazole could be attributed to
covalent adduct formation with essential thiols and the
proteins described, leading to impaired protein function
(Figure 6). Arguably, the formation of covalent adducts and
oxidative stress could even intertwine, because metronidazole
toxicity was shown to be exacerbated in E. histolytica under
microaerophilic conditions as compared to metronidazole
treatment in the complete absence of oxygen [43]. At ﬁrst
glance, this is counterintuitive, because our results show that
higher oxygen levels lead to less non-protein thiol depletion
(Figure 3A). Moreover, azomycin is by far less toxic to E.
histolytica than metronidazole although it gives rise to more
superoxide anion radicals (Table 2). However, azomycin
forms fewer adducts with the ﬁve proteins identiﬁed, of
which three, i.e., superoxide dismutase, thioredoxin reduc-
tase, and thioredoxin, are known to be involved in antiox-
idant defense. We show here that metronidazole-modiﬁed
recEh TrxR displays a considerably reduced thioredoxin
reductase activity. Thus, it is conceivable that the higher
sensitivity of E. histolytica to metronidazole in the presence of
oxygen is not due to a increased toxicity of metronidazole
itself, but due to a reduced tolerance to oxygen because the
cell’s capability to remove harmful oxidants is impaired.
Thioredoxin, for example, requires prior reduction by
thioredoxin reductase in order to reduce peroxiredoxin
[44,45], an enzyme that oxidizes hydrogen peroxide to water
and oxygen. Since, in contrast to thioredoxin reductase
activity, the nitroreductase activity of thioredoxin reductase
is not diminished by metronidazole binding, superoxide
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oxygen by activated nitroimidazoles. Superoxide dismutase
breaks down superoxide radical anions to oxygen and
hydrogen peroxide. The latter would then accumulate due
to a reduced peroxiredoxin activity.
In any case, even in the complete absence of oxygen,
metronidazole is a potent drug, suggesting that adduct
formation of nitroimidazoles with the proteins identiﬁed
and with non-protein thiol compounds can be very effective
in killing E. histolytica cells (Figure 6). In addition, because
mRNA expression was unchanged during metronidazole-
exposure with 50 lM metronidazole (M. Tazreiter, unpub-
lished data) and higher doses (e.g., 1 mM) of metronidazole
rapidly led to the disintegration of cells, we do not believe
that DNA damage plays a decisive role in short-term
metronidazole-mediated toxicity.
Finally, because thioredoxin reductase is a ubiquitous
enzyme, we suggest that our proposed model of metronida-
zole action might also, at least partly, apply for other
organisms. Our preliminary data from 2D gels of, for
example, T. vaginalis extracts corroborate the ﬁndings
presented and discussed in this study, because thioredoxin
reductase was identiﬁed among the proteins modiﬁed in this
parasite.
Materials and Methods
Cell culture. E. histolytica HM-1:IMSS cells were grown axenically at
36.5 8C in culture ﬂasks that were completely ﬁlled with TYI-S-33
medium [46] and carefully sealed in order to ensure low oxygen
tension. Culture medium was changed every 3 d. Es. coli BL21 (DE3)
was grown in LB medium with appropriate antibiotics. Agar plates
contained 15 g/l of agar.
When non-protein thiol levels were measured in E. histolytica while
applying deﬁned oxygen tensions, culture ﬂasks were only half ﬁlled
with growth medium, sealed with a vented plug, and then
preincubated for 1 d either in tightly sealed jars containing Merck
Anaerocult A (Merck, http://www.merck.de/) for anaerobic conditions
(0% O2 and 18% CO2) or Merck Anaerocult C for microaerophilic
conditions (5% O2 and 8% CO2) or in a normal incubator in the
presence of air (21% O2 and 0.4% CO2) for aerobic conditions. Cell
cultures were then harvested, followed by the resuspension of the cell
pellets in the respective preincubated media and the exposure to
metronidazole or to azomycin as stated below.
Cell harvest and preparation of cell lysates. Cells were harvested by
centrifugation at 500g at room temperature for 5 min and then
washed twice with PBS to remove residual serum components. Cell
lysates for 2DE were prepared as described previously [39]. Brieﬂy,
proteins were precipitated with trichloroacetic acid and acetone, and
solubilized in a classical buffer containing urea, thiourea, CHAPS,
and DTT.
2DE and image analysis. 2DE was performed as described
previously [39]. Analytical gels were silver stained [47], whereas
preparative gels were stained with Coomassie Brilliant Blue R-250.
After staining, gels were scanned with an Epson 1680 Pro scanner
Figure 6. Model of Metronidazole Activation and Metronidazole Action in E. histolytica
After uptake by the cell, metronidazole is reduced by thioredoxin reductase (TrxR) (as shown in this study; black arrow), possibly by purine nucleoside
phosphorylase (hypothesized in this study; dotted arrow) and, probably, by ferredoxin (shown to reduce metronidazole in T. vaginalis and G. intestinalis;
interrupted arrow). After activation, metronidazole can develop its toxicity in a 2-fold way, either as a nitroradical anion or, if further reduced, as a
reactive nitrosoimidazole (red arrows). The nitroradical anion can reduce O2 and thereby generate reactive oxygen species, which are highly detrimental
to the microaerophilic E. histolytica cell. Alternatively, the nitrosoimidazole is generated, which forms adducts with non-protein thiols and/or proteins,
resulting in the depletion of non-protein thiols and the modification of thioredoxin reductase (TrxR), thioredoxin (Trx), superoxide dismutase (SOD),
metronidazole target protein 1 (Mtp1), and purine nucleoside phosphorylase (PNP). Presumably, these five proteins become targets of modification due
to their close spatial proximity to the site of metronidazole activation, i.e., thioredoxin reductase. The formation of covalent metronidazole adducts with
proteins involved in antioxidant defense is likely to render the cells more vulnerable to oxidative stress, thereby exacerbating metronidazole toxicity to
E. histolytica in the presence of oxygen [43].
doi:10.1371/journal.pbio.0050211.g006
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analysis software (GeneBio, http://www.genebio.com/).
Protein identiﬁcation and mass spectrometry of intact proteins.
The excised 2DE spots were destained, digested with trypsin, and
analyzed by LC-ESI-QTOF-MS as described previously [48]. For
protein identiﬁcation, the MS/MS data were subjected to database
search against the SwissProt database using the Mascot search engine
(http://www.matrixscience.com/) and Protein Global Server 2.1
(Waters-Micromass, http://www.waters.com/). A compilation of mass
data is given in Figures S1–S5.
The mass of intact proteins with and without metronidazole or
tinidazole treatment (see above) was determined using LC-ESI-
QTOF-MS. An aliquot corresponding to approx 500–1,000 pmol of
puriﬁed protein (recombinantly produced in Es. coli) was subjected to
liquid chromatography (LC) using a BioBasic C4 column (30 3 0.32
mm; Thermo Electron Corporation, http://www.thermo.com/) using a
CAP-LC (Waters-Micromass). Proteins were loaded onto the column
in solvent A (water containing 0.1% formic acid) and eluted using a
gradient from 0%–70% solvent B (acetonitrile containing 0.1%
formic acid) in 30 min. The ﬂow rate was held at 5 ll/min throughout
the analysis. Instrument calibration and tuning in the mass range
from 500–4,000 Da was achieved using a 2 mg/ml solution of sodium
iodide in 50% isopropanol. Spectra were deconvoluted using
MaxEnt1 function of the MassLynx 4.0 SP4 software (Waters-
Micromass).
Estimation of non-protein thiol concentrations in metronidazole-
treated and untreated cells. The levels of non-protein thiols in
metronidazole-treated, azomycin-treated, or in untreated cells were
determined as described [49]. Brieﬂy, cells were harvested and washed
in 20 mM EDTA. Pellets were resuspended in 20 mM EDTA, and cells
were disrupted by repeated freezing and thawing. Cell debris was
removed by centrifugation at 20,000g for 15 min. After measuring
protein levels with Bradford reagent, equal amounts of protein were
precipitated in 5% TCA at room temperature, followed by
centrifugation at 20,000g for 15 min. Supernatants containing the
non-protein thiols were removed, and the double volume of 0.4 M
Tris/HCl (pH 8.9) was added. A total of 1.7 ll 100 mM 5,59-dithiobis-
(2-nitrobenzoic acid) (DTNB) per ml reaction mixture was added.
Reduction of DTNB was measured at k ¼ 412 nm in a Jenway 6505




Cysteine protection assay. Before addition of various amounts of
metronidazole and/or cysteine, total and viable cell numbers were
determined by trypan blue exclusion in a Bu ¨rker-Tu ¨rk hemocytom-
eter. After addition of reagents, cells were incubated for 20 h at 36.5
8C. After incubation, total and viable cell numbers were redeter-
mined.
Expression of recombinant hexahistidine-tagged thioredoxin and
thioredoxin reductase in Es. coli. The genes for thioredoxin reductase
and thioredoxin were ampliﬁed from genomic E. histolytica HM-
1:IMSS DNA. Primers were 59-TAC GTA CGC ATA TGA GTA ATA
TTC ATG ATG TTG TGA TTA TCG GC-39 (TrxR forward) and 59-
TCA TCC AGC TCG AGT TAG TGG TGA TGG TGA TGA TGA GTT
TGA AGC CAT TTT TCA CAG-39 (TrxR reverse) for thioredoxin
reductase, and 59-TAC GTA CGC ATA TGG CTG TAC TTC ATA
TTA ACG CTC TTG ATC AA-39 (Trx forward) and 59-TCA TCC AGC
TCG AGT TAG TGA TGG TGA TGG TGA TGT CGT GTT TCA ACC
ATT TGT TTT AAG GCA-39 (Trx reverse) for thioredoxin. Forward
primers include an NdeI restriction site, whereas reverse primers
bear an XhoI restriction site and a hexahistidine tag for convenient
protein isolation. PCR fragments were ligated into the pET 17b
vector (Novagen/VWR, http://www.emdbiosciences.com/html/NVG/
home.html). The plasmid sequences were conﬁrmed on both strands
by using T7 and pET reverse primers (GATC Biotech, http://www.
gatc-biotech.com/en/index.php). The conﬁrmed plasmids were trans-
fected into Es. coli BL21(DE3) cells. Transformants were selected on
20 lg/ml ampicillin. Expression of recombinant proteins was induced
by addition of 0.5 mM IPTG. If proteins were to be modiﬁed with
metronidazole, 1 mM metronidazole was added to the LB medium,
and cells were grown in completely ﬁlled tissue culture ﬂasks under
exclusion of air. Three hours after induction, cells were harvested and
then disrupted by vigorous grinding in a mortar. Subsequently,
recombinant proteins were puriﬁed via Ni-NTA spin columns
(Qiagen, http://www1.qiagen.com/). Recombinantly expressed E. histo-
lytica thioredoxin and E. histolytica thioredoxin reductase are referred
to as recEh Trx, and recEh TrxR, respectively.
Assaying disulﬁde reductase activity of recEh TrxR. The assay was
performed as described elsewhere [50] using recEh Trx and recEh
TrxR in combination. The reaction buffer contained 100 mM
potassium phosphate (pH 7.5), 1 mM EDTA, 1 mM DTNB, and 0.5
mM NADPH. All reactions were done with 2 lg/ml recEh Trx and 5
lg/ml recEh TrxR. RecEh TrxR oxidized NADPH to NADP in order to
reduce the disulﬁde bond at the active site of recEh Trx, which, in
turn, reduced DTNB. Ongoing reduction of DTNB was measured at k
¼ 412 nm (De412 ¼ 13.6 mM
 1 cm
 1) over a period of 5 min at 25 8C.
Assaying nitroreductase activity of recEh TrxR. Reduction of
CDNB by Eh TrxR was measured by determining NADPH con-
sumption at k¼340 nm (De340¼6.2 mM
 1 cm
 1). The reaction buffer
contained 100 mM potassium phosphate (pH 7.5), 1 mM EDTA, and
0.1 mM NADPH. Reduction of CDNB was determined at a
concentration of 100 lM. For reasons of practicability, because
nitroimidazoles display high absorbances at k ¼ 340 nm and thereby
heavily disturb the assay, reduction of nitroimidazoles was measured
in a modiﬁed assay [30] via reduction of cytochrome c at k¼ 550 nm
(De550 ¼ 20 mM
 1 cm
 1), either directly by reduced nitro compounds
(CDNB, azomycin, and metronidazole), or indirectly by superoxide
radical anions that are generated when nitroradicals transfer an
electron to molecular oxygen in the reaction buffer. In any case, nitro
compounds had been previously reduced by recEh TrxR. Therefore,
it was assumed that reduction of one nitro group by Eh TrxR
subsequently resulted in one reduced cytochrome c molecule.
Reaction mixtures contained 100 mM potassium phosphate (pH
7.5), 1 mM EDTA, 0.5 mM NADPH, 50 lM cytochrome c, 4 lg/ml
recEh TrxR (equal to 118 nM) and different amounts of CDNB,
azomycin, or metronidazole, respectively. Reduction of cytochrome c
was measured over a time span of 5 min at 25 8C. In order to assess
the proportion of electrons that are directly transferred from the
reduced nitro compounds to cytochrome c, 2.5 lM bovine eryth-
rocyte superoxide dismutase (i.e., an approximately 20-fold excess
over Eh TrxR) were added to the reactions to remove all generated
superoxide radical anions. Bovine erythrocyte superoxide dismutase
was purchased from Sigma (http://www.sigmaaldrich.com/).
Supporting Information
Figure S1. Sequence of E. histolytica Superoxide Dismutase (P34107)
and Peptides Identiﬁed by MS/MS
(A) Based on the MS/MS spectrum and the particular mass differ-
ences, the Ser in position two was identiﬁed to be acetylated after
removal of the amino-terminal Met. The identiﬁed peptide sequences
are in red.
(B) MS/MS spectrum of the tryptic peptide 2–21. Ser in position 2 was
amino-terminally acetylated after removal of the Met.
(C) MS/MS spectrum of peptide 97–109.
(D) MS/MS spectrum of peptide 171–184.
Found at doi:10.1371/journal.pbio.0050211.sg001 (45 KB PDF).
Figure S2. Sequence of E. histolytica Metronidazole Target Protein 1
(Q50UL1) and Peptides Identiﬁed by MS/MS
(A) MS/MS spectrum of peptide 43–57. The identiﬁed peptide
sequences are in red.
(B) MS/MS spectrum of peptide 58–77.
Found at doi:10.1371/journal.pbio.0050211.sg002 (38 KB PDF).
Figure S3. Sequence of E. histolytica Thioredoxin Reductase (Q50PB3)
and Peptides Identiﬁed by MS/MS
(A) Based on the MS/MS spectrum and the particular mass differ-
ences, the Ser in position 2 was identiﬁed to be acetylated after
removal of the amino-terminal Met. The identiﬁed peptide sequences
are in red.
(B) MS/MS spectrum of peptide 2–25. Ser in position 2 was amino-
terminally acetylated after removal of the Met.
(C) MS/MS spectrum of peptide 261–273.
(D) MS/MS spectrum of the carboxy-terminal peptide 292–314.
Found at doi:10.1371/journal.pbio.0050211.sg003 (50 KB PDF).
Figure S4. Sequence of E. histolytica Thioredoxin (Q51ER4) and
Peptides Identiﬁed by MS/MS
(A) Based on the MS/MS spectrum and the particular mass differ-
ences, the Ala in position 2 was identiﬁed to be acetylated after
removal of the amino-terminal Met. The identiﬁed peptide sequences
are in red.
(B) MS/MS spectrum of peptide 2–20. Ala in position 2 was amino-
terminally acetylated after removal of the Met.
(C) MS/MS spectrum of peptide 36–52.
Found at doi:10.1371/journal.pbio.0050211.sg004 (35 KB PDF).
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Thioredoxin Reductase and Nitroimidazole ActionFigure S5. Sequence of E. histolytica Purine Nucleoside Phosphorylase
(Q51AY9) and Peptides Identiﬁed by MS/MS
(A) On the amino terminus, the ﬁrst two amino acids (Met and Cys)
appear to be removed because a peptide corresponding to positions
3–13 was identiﬁed. After removal of Met1 and Cys2, amino-terminal
Ala at position 3 is apparently acetylated, as already observed in most
of the other samples. The identiﬁed peptide sequences are in red.
(B) MS/MS spectrum of peptide 3–13. Ala in position 3 was amino-
terminally acetylated after removal of the Met and Cys.
(C) MS/MS spectrum of peptide 61–75.
(D) MS/MS spectrum of peptide 288–311.
Found at doi:10.1371/journal.pbio.0050211.sg005 (50 KB PDF).
Accession Numbers
The National Center for Biotechnology Information (http://www.ncbi.
nlm.nih.gov/) accession numbers for the proteins discussed in this
paper are as follows: a-amylase (XP_652601), metronidazole target
protein 1 (XP_650662), purine nucleoside phosphorylase
(XP_655398), superoxide dismutase (XP_648827), thioredoxin
(XP_656726), and thioredoxin reductase (XP_655748).
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